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Central sensitizationSuperoxide (SO, O2·
−) and its reaction product peroxynitrite (PN, ONOO−) have been shown to be important
in the development of pain of several etiologies. While signiﬁcant progress has been made in teasing out the
relative contribution of SO and PN peripherally, spinally, and supraspinally during the development and
maintenance of central sensitization and pain, there is still a considerable void in our understanding. Further
research is required in order to develop improved therapeutic strategies for selectively eliminating SO and/or
PN. Furthermore, it may be that PN is a more attractive target, in that unlike SO it has no currently known
beneﬁcial role. Our group has been at the forefront of research concerning the role of SO and PN in pain,
and our current ﬁndings have led to the development of two new classes of orally active catalysts which
are selective for PN decomposition while sparing SO. This article is part of a Special Issue entitled: Antioxi-
dants and Antioxidant Treatment in Disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Pain is a global afﬂiction that affects people of every age, gender,
and ethnicity. In the United States alone, the American Pain Society
estimates that about 105 million people suffer from chronic pain [1].
Global pain market sales in 2009 exceeded $50 billion [1]. This does
not take into account the indirect costs such as loss of productive
work time and decreased quality of life. Most current strategiesylpiperidine 1-oxyl; AP-1, acti-
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rights reserved.of pain management involve traditional non-steroidal anti-
inﬂammatory drugs (NSAIDs) and opioid narcotics. NSAIDs have lim-
ited efﬁcacy and while opioids are highly efﬁcacious in the treatment
of pain, their use is severely limited by debilitating side effects, the
risk of addiction, the development of tolerance [2], and potentially
morphine-induced hyperalgesia [3]. Selective cyclooxygenase
(COX)-2 inhibitors have been shown to be effective in certain types
of chronic pain, however concerns over their side-effects including
increased risks of heart attack and stroke [4] have led to a decline in
their use. Thus it is clear that there is a desperate need for new
analgesic agents that would maintain efﬁcacy over long-term treat-
ment without the risk of tolerance, addiction, or intolerable side
effects.
There is signiﬁcant evidence linking both superoxide (SO, O2·−)
and peroxynitrite (PN, ONOO−) to pain of several etiologies. Because
SO and PN contribute to the development and maintenance of both
peripheral and central sensitization, they are attractive targets for
pain management strategies as will be discussed further in later
sections. Indeed, current studies have shown that therapeutic
strategies targeting SO and PN are able to both prevent and reverse
the pathologies associated with pain of various etiologies.
Modulation of protein kinases, alterations in glutamatergic neuro-
transmission, neuroinﬂammation, and modulation of ion channels are
some of the hallmarks of the development of central sensitization
and can occur in the periphery, spinal cord, or supraspinally. Both SO
and PN have been shown to be involved in these signaling pathways
(Fig. 1). In this review, we will brieﬂy discuss the contributions of SO
and PN in pain as well as current therapeutics and future directions
for the targeting of these important species.
Fig. 1. Peroxynitrite modulates central sensitization through a variety of mechanisms.
Peroxynitrite (PN) formed within the periphery, the spinal cord, and in supraspinal
areas modulates central sensitization associated with pain of several etiologies. Path-
ways known to be potentially impacted as a result of overt formation of PN are
depicted.
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Our improved understanding of SO and PN in pain, has led to the
development of therapeutic strategies based on their elimination
(Fig. 2). There are two major strategies pursued in the effort to target
SO and PN: preventing the formation of PN and decomposing the PN
that already exists [5]. Several metal-based catalysts and non-metal
scavenger systems [6] have been reported to effectively prevent the
formation of PN through the dismutation of SO (superoxide
dismutase mimetics, SODms) or to decompose PN once it is formed
(PN-decomposition catalysts, PNDCs) [7,8]. The two most promising
classes of therapeutic agents are synthetic porphyrins (e.g. MnTE-2-
PyP5+, FeTM-4-PyP5+), and functionalized manganese(II) polyazama-
crocycles (e.g. SC-72325) [6]. While both of these classes will act as
SODms, the metalloporphyrins also act as PNDCs [6,9] making them
excellent candidates for potential therapeutic agents. An orally
available PNDC, Fe(III)tetrakis-2-(N-triethylene glycol monomethyl
ether) pyridyl porphyrin, has been shown to prevent the development
of diabetic neuropathic pain [10,11]. We have recently described the
synthesis and evaluation of a new lipid soluble manganese(III) porphy-
rin, SRI6 [12]. SRI6 is able to shield the charged metal center from theFig. 2. Therapeutic strategies targeting peroxynitrite. Targeting peroxynitrite (PN) with
superoxide dismutase mimetics (SODm), peroxynitrite decomposition catalysts
(PNDCs) which also have SODm activity, or with SO-sparing PNDCs (e.g. SRI6,
SRI110) may provide a promising novel therapy for pain management.membrane during passive transport by employing beta-fused cyclo-
hexenyl substituents. It has therefore been shown to be orally active
in a number of animal models of inﬂammatory and neuropathic pain.
Because of the removal of charged electron-withdrawing meso-
functionality used for PNDCs (such as FeTMPyP5+), the metal-
centered reduction potential for SRI6 is out of the useful range for
SOD activity [13] but well within the oxygen atom transfer reactivity
manifold of PN [14]. Thus, our design for oral activity runs in parallel
with selectivity for decomposing PN while sparing SO. We have also
extended this design to a new class of 2-electron PN reducing catalysts,
exempliﬁed by SRI110 [15,16]. SRI110 and similar analogs have been
shown to react with PN to produce the manganese(V)O intermediate
with concomitant reduction of PN to nitrite. The manganese(V)O
species are rapidly reduced to the manganese(III) resting form of the
catalyst by endogenous reductants completing a reductase type cycle.
Neither SRI6 nor SRI110 has appreciable reactivity toward SO as
determined by the xanthine/xanthine oxidase assay [17] and both are
effective in blocking acute and chronic neuropathic thus supporting
the key role of peroxynitrite in these settings pain [15,16].
3. Roles of SO and PN in pain
Superoxide itself a powerful reactive oxygen pro-nociceptive spe-
cies, will combine with nitric oxide (NO) to form PN which is also a
potent pro-nociceptive nitroxidative species [18]. These discoveries
were made possible by the use of SODms (e.g. SC-72325) and PNDCs
(e.g. FeTM-4-PyP5+ and MnTE-2-PyP5+) as tools to dissect out the
signaling pathways that these species are involved in. The direct
contribution of SO and PN to the development of pain has since been
demonstrated by intraplantar injection, which led to the development
of hyperalgesia [19,20]. Additionally, increased formation of PN/SO has
been shown to be important to the development of thermal hyperalge-
sia associated with acute and chronic inﬂammation [20], in the
development of orofacial pain [21], and in the development of opiate-
induced hyperalgesia and antinociceptive tolerance [22]. Furthermore,
a role for SO and PN in pain has been supported using a variety of non-
selective agents such as phenyl N-tert-butylnitrone (PBN) and
4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPOL) which
have shown efﬁcacy in various pain states including inﬂammatory
pain [23], neurogenic pain [24], neuropathic pain [24–27], and
chemotherapy-induced pain [28,29]. Recent studies have shown that
treatment with PBN was able to prevent the development or inhibit
established paclitaxel-induced mechanical hypersensitivity [28,29]
while TEMPOL treatment was able to only reverse its development
[29] leading them to believe that reactive oxygen species but not
superoxide alone play a causative role in paclitaxel-induced neuro-
pathic pain. As emphasized in several review articles [13,30–32] non-
selective agents such as TEMPOL or PBN cannot be used to delineate
the contribution of a speciﬁc nitroxidative species (i.e. SO vs. PN),
since these agents will removemany reactive oxygen and nitrogen spe-
cies including but not limited to NO, SO, PN and hydroxyl radicals
[30–32]. When using these non-selective probes it is important to
keep this in mind and discuss results more generally and in terms of
“nitroxidative stress and nitroxidative species for instance” rather
than implicating/excluding a speciﬁc species such as SO or PN. This
may otherwise lead to inappropriate conclusions and importantly mis-
interpretation of results.
4. Pathways leading to SO and PN formation
Understanding the enzymatic pathways that lead to the formation
of SO and PN is a critical step in targeting it. When SO and NO produc-
tion is increased, PN is preferentially formed as SO has a greater reac-
tivity with NO than with mitochondrial manganese superoxide
dismutase (MnSOD) [33] which normally keeps the levels of SO
under control [34]. Furthermore, PN can inactivate MnSOD by nitrating
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mechanism, PN-driven inactivation of MnSOD results in the overpro-
duction SO leading to increased levels of PN [36]. Our group has
shown that spinal tyrosine nitration and thus inactivation of MnSOD
results in the accumulation of SO and PN during the development
and maintenance of central sensitization associated with pain of
several etiologies and in the development of opiate induced hyperalge-
sia and antinociceptive tolerance [37]. Another important source of
these species is from the mitochondrial electron transport chain.
Mitochondria consume about 85% of the oxygen utilized by the cell
and are a major source of SO production [38]. PN indirectly promotes
the reduction of oxygen to SO by increasing protein kinase C (PKC)
activity (which will be further discussed in Section 5.1) leading to
increased nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase activity. NADPH oxidase produces SO upon activation eventu-
ally resulting in the formation of PN [39]. We have therefore proposed
that post-translational nitration and inactivation of MnSOD and activa-
tion of NADPH oxidase represent two pathways that together contrib-
ute to the maintenance of central sensitization [32].
5. SO and PN in nociceptive signaling
There are many factors involved in the development of central
sensitization associated with acute and chronic inﬂammatory and
non-inﬂammatory neuropathic pain (Fig. 1). This includes but is not
limited to modulation of protein kinases, alterations in glutamatergic
neurotransmission, neuroinﬂammation, and modulation of ion chan-
nels. These changes may occur in the periphery, in the spinal cord,
and at supraspinal sites. Although a thorough understanding of the
role of SO and PN in central sensitization is not yet understood, it is
apparent that all of these signaling pathways involved in central
sensitization can be inﬂuenced by them. Due to limits on space, we
will brieﬂy describe these signaling pathways and refer to review
articles whenever possible.
5.1. Interaction of SO and PN with protein kinases
Protein kinases play a vital role in many of the signal transduction
pathways involved in the development of peripheral and central sensi-
tization. PKC activation has been shown to be required for the develop-
ment of peripheral [40] and central sensitization [41] in several pain
states. The inﬂuence of PKC on the development of pain can be seen
in several pathways. In the periphery, activation of PKC has been
shown to depolarize unmyelinated afferent neurons, sensitize afferent
neurons, enhance currents in afferent neurons, and when inhibited can
block sensitization in afferent neurons [42]. In the central nervous sys-
tem (CNS), PKC can be activated both in the neurons and astrocytes.
Upon such stimulation as peptide neurotransmitters or glutamatergic
receptor stimulation [41], PKC can be activated leading to enhanced
synaptic plasticity by increasing excitability, shortening the latency to
ﬁrst spike, increasing spike frequency, and increasing action potential
amplitude [42]. Protein kinase A (PKA) activity has been shown to be
important in the phosphorylation and activation receptors such as
the N-methyl-D-aspartate receptor (NMDAR) as well as increasing
COX-2 protein expression [43]. Likewise, calcium/calmodulin-
dependent protein kinase II (CaMKII) activity has been shown to
increase synaptic strength via modulation of receptors [43].
The modulation of these protein kinases therefore is extremely
important to peripheral and central sensitization. Both SO and PN
are capable of activating PKC [44–46]. PN does this either by direct ni-
tration [45] or by stimulating proteolytic activation of PKC [46]. The
evidence for SO and PN's involvement with PKA and CAMKII is less
clear-cut; however there is some indirect evidence of it. PBN, an anti-
oxidant, reduced the levels of PKA-speciﬁc NMDA receptor phosphor-
ylation and attenuated capsaicin-induced hyperalgesia [24].
Additionally, PN decomposition prevented prostaglandin (PG)E2-mediated thermal hyperalgesia and potential downstream PKA activ-
ity following intraplantar SO administration [20].
5.2. Effect of SO and PN on COX enzymes
Another way by which SO and PN may inﬂuence central sensitiza-
tion is through modulation of the COX enzymes since it is well
known that spinal prostaglandins play key roles in pain and in particu-
lar inﬂammatory pain [47]. The COX enzymes (COX-1 and COX-2) have
long been known as targets of NO [48]. Since then it has been shown
that PN plays a role in the activation of COX enzymes by modulating
key amino acids residues in the polypeptide backbone [49]. Conse-
quently, PN can increase COX-2 protein levels and stabilize its mRNA
which can ultimately result in an increase in the release of prostaglan-
dins [50]. This activation of COX enzymes by NO and PN and the
ensuing release of proinﬂammatory and pronociceptive prostaglandins
contributes to the development of peripheral sensitization during
inﬂammation [20]. This interaction of NO and PN with the COX
enzymes is more fully described in Mollace et. al. (2005) [51].
5.3. Impact of SO and PN on glutamatergic neurotransmission
One of the most important roles of PN in the development of
central sensitization may be its ability to affect glutamatergic signaling
via nitration of vital proteins involved in glutamatergic neurotransmis-
sion. Glutamate is a critical neurotransmitter involved in the develop-
ment of inﬂammatory pain [52], neurogenic pain [53], neuropathic
pain [54] and in the development of opioid hyperalgesia/tolerance
[55]. Glutamate is the primary endogenous ligand for NMDAR. PN can
irreversibly nitrate the tyrosine residues present on NR1, a subunit of
NMDAR leading to a constant activation of the receptor ultimately
resulting in excitotoxicity [56]. PN can also indirectly affect NMDARs
through activation of PKC leading to enhanced NR1 phosphorylation
[57]. Increased neuronal activity has been linked to the development
of central sensitization associated with pain of several etiologies and
the inhibition of NMDAR activation has been shown to reduce neuronal
activity [58].
In order to maintain proper neuronal activity, the extracellular
glutamate concentration must be highly regulated to control receptor
activation and to protect the neuron from excitotoxicity [59]. Gluta-
mate transporters (GTs) located within the plasma membranes of
both the neuron and the glia are responsible for removing glutamate
from the synapse and extrasynaptic regions [60]. Of the ﬁve mem-
brane subtypes that have been cloned, three in the spinal cord are
considered essential to maintain proper glutamate levels: GLAST
(EAAT1), GLT-1 (EAAT2), and EAAC1 [61]. The ﬁrst two are found
on glial cells, while the last is found on neurons. The GTs in glia are
responsible for more than 90% of total glutamate transport [62]. If
these transporters are nitrated, their inactivation results in increased
glutamate concentration and altered synaptic transmission [63].
These transporters also play a role in the reuptake of cysteine, an im-
portant part in the biosynthesis of glutathione (GSH). GSH protects
the cell from oxidative stress and depletion of it results in enhanced
oxidative stress leading to neuronal degeneration [64]. Additionally,
glutamate synthetase (GS), which catalyzes the conversion of gluta-
mate and ammonia to glutamine, can be inactivated via nitration by
PN [65]. Inactivation of GS has been linked to pain of various
etiologies [22,66]. Therefore, PN has the ability to alter glutamatergic
signaling by various means ultimately resulting in central sensitization.
5.4. Inﬂuence of SO and PN on neuroinﬂammation
Neuroinﬂammation has been shown to be instrumental in the de-
velopment and maintenance of central sensitization [67]. Glial cells
(astrocytes and microglia) once activated via various substances in-
cluding neurotransmitters and proinﬂammatory mediators [68,69]
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alterations in morphology, increased expression of speciﬁc cell surface
markers, increased secretion of certain proteins, and increased glial cell
proliferation [70]. Spinal glial cells in an enhanced response state have
been found to be inﬂuential in the development of pathological pain
associated with a number of pain syndromes [69]. In an enhanced re-
sponse state, glial cells can release pro-inﬂammatory cytokines (e.g.
TNFα, IL-1β, and IL-6) and nitroxidative species (e.g. NO, SO, and
PN), which can then sensitize the neurons in the dorsal horn leading
to pain [68,69]. These glial-derived pro-inﬂammatory mediators act
not only on neurons, but also on glial cells leading to an ampliﬁcation
loop [71].
The proinﬂammatory cytokines tumor necrosis factor (TNF)-α and
interleukin (IL)-1β contribute to central sensitization by initiating
several pathways including the inhibitor of κBα (IκBα), c-Jun
N-terminal kinase (JNK), and p38 pathways which in turn promote
proinﬂammatory cytokine transcription through nuclear factor κB
(NFκB) and activator protein (AP-1) [72,73].
PN has been shown to contribute to central sensitization in
inﬂammation and chronic morphine administration by increasing the
formation of glial-derived cytokines within the spinal cord [18,22].
PN is able to activate NFκB and several mitogen-activated protein ki-
nases (MAPKs) (e.g. p38 and ERK1/2) which are responsible for the
regulation of many proinﬂammatory mediators and cytokines
[74–76]. Additionally, PN can initiate poly (ADP-ribose) polymerase
(PARP) activation [77] whose activity has been linked to MAPK
activation [78] and the production of proinﬂammatory cytokines [79].
Administration of a SODmwas able to prevent the increased formation
of pro-inﬂammatory cytokines in spinal cord and attenuate the devel-
opment of hyperalgesia [19,22,37]. Thus PN can contribute to central
sensitization via neuroinﬂammation and the subsequent release of
glial-derived pro-inﬂammatory cytokines.
5.5. Interaction of SO and PN with TRP channels
Transient receptor potential cation channel, subfamily V, member
1 (TRPV1) has been shown to be activated both by endogenous and
exogenous pain stimuli [80]. These receptors have been found in the
periphery and the CNS and have been shown to be required during
inﬂammatory thermal hyperalgesia [81]. TRPV1 has been associated
with increased glutamatergic signaling [82] and the facilitation of
long-term potentiation [83], which are both important to central sensi-
tization. TRPV1 activation can be achieved via phosphorylation by PKA,
PKC or CAMKII [84,85]. Modiﬁcation of cysteine residues on TRPV1
results in the resistance to desensitization, the sensitization of normal
receptors, and the reactivation of desensitized TRPV1 [86]. Ultimately,
this may lead to persistent pain signaling in nociceptive neurons [86].
Therefore SO and PN may indirectly inﬂuence TRPV1. Furthermore, it
was recently shown that activation of TRPV1 in retinal explants en-
hanced a biomarker of PN-mediated protein nitration, 3-nitrotyrosine
[87].
5.6. Involvement of SO and PN with GABA
γ-Aminobutyric acid (GABA) is involved in modulating the inhibi-
tory synaptic transmission within the spinal cord [88]. It is well estab-
lished that a disruption in the spinal GABAergic system can contribute
to the development of neuropathic pain. The mechanisms behind this
loss of inhibition are still not clearly understood. Interestingly a recent
study demonstrated that PBN administered either systemically or
intrathecally could temporarily reverse mechanical hyperalgesia by
reducing spinal GABA release while not interfering with glycine trans-
mission in a model of spinal nerve ligation [89]. This led the authors to
conclude that excessive levels of reactive oxygen species within the
spinal cord may then play a role in the induction of pain by interfering
with spinal inhibitory transmission via the inhibition of GABArelease. Additional work to tease out this relationship is therefore
warranted.
5.7. Role of SO and PN in supraspinal nociceptive modulation
Supraspinal nociceptive modulation is essential to the development
andmaintenance of pain states [90]. The role of SO and PN in this process
is unclear, however it has recently been shown that PN-mediated activity
occurs in the brain during morphine antinociceptive tolerance and is
prevented with PNDCs (MnTnHex-2-PyP5+ and MnTE-2-PyP5+) [91].
Additionally, intracerebroventricular injections of free radical scavengers
(e.g. PBN) are able to attenuate inﬂammation and nerve injury-induced
hypersensitivity to both noxious and non-noxious stimuli [92,93].
The rostral ventromedial medulla (RVM) is an important region for
supraspinal nociceptive modulation where nitroxidative species may
functionally contribute [31]. The RVM is responsible for instigating
spinal mechanisms that result in both responsiveness and non-
responsiveness to neuropathic pain [94]. It contributes to the develop-
ment and maintenance of central sensitization by engaging descending
facilitation. Descending facilitation is a result of numerous alterations
to the local microenvironment and depends upon NO (the precursor
of PN) [95]. Many of the changes that occur within the RVM during
descending facilitation are similar to those seen within the spinal
cord during central sensitization [96–99]. These changes include pro-
tein kinase activation, enhanced glutamatergic neurotransmission,
and neuroimmune activation which are all inﬂuenced by SO and PN
in the spinal cord. This led us to our hypothesis and current line of
study which suggests that nitroxidative species within the RVM
contribute to central sensitization [100,101]. Additionally, support
exists for a speciﬁc supraspinal locus that modulates nociception
during oxidative stress in that reactive oxygen species in the amygdala
activate the type 1 metabotropic glutamate receptor to enhance noci-
ception [102,103].
6. Future directions
We are currently limited by the lack of compounds that can selec-
tively target SO or PN. To further our understanding of the contribution
of SO and PN in pain, it is necessary that better pharmacological tools
be made available. The metalloporphyrin-based PN scavengers are
very promising candidates in strategies that target PN and SO in a stan-
dalone mode or that work in combination with other analgesics
(Fig. 2). Since metalloporphyrin systems have evolved in nature to be
encased in protein (e.g. the cytochromes), small molecule porphyrin-
based PNDCs will require peripheral synthetic modiﬁcation to impart
human pharmaceutical properties (e.g. membrane solubility, reduced
charge, reduced non-target binding, reduced toxicity, optimal pharma-
cokinetics, etc.). As the metal center in these systems is the site for
antioxidant action, the periphery of the porphyrin macrocycle and
other catalyst ligand systems are wide-open for synthetic manipula-
tions aimed to control in vivo performance without negative perturba-
tion of the catalytic apparatus. As we have seen with SRI6 and SRI110,
not only can we enhance drug-like properties through a medicinal
chemistry approach, but we can also engineer unique modes of
catalytic activity (e.g. selectivity for PN removal over SO). We believe
that through further combinations of medicinal chemistry and catalysis
chemistry explorations of the ligand periphery, true drug candidates
with tuned selectivities can be engineered.
We have also recently explored the role of PN in chemotherapy-
induced peripheral neuropathy (CIPN). Peripheral neuropathy is the
most common treatment-limiting complication in cancer patients
receiving several ﬁrst-line chemotherapeutics including paclitaxel,
oxaliplatin, and bortezomib [104]. CIPN severely limits the usefulness
of these drugs and seriously hampers the ability to treat cancer effec-
tively. We have recently observed that treatment with a PNDC is able
to both prevent and reverse the development of CIPN regardless of
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with its anti-tumor effects [105,106]. These ﬁndings could potentially
save countless lives, as it would allow for chemotherapeutics to be
used at more efﬁcacious dosages.
7. Conclusions
It is eminently clear that there is a void in current analgesic thera-
peutic treatments. As more of the roles of SO and PN in the develop-
ment and maintenance of pain are unveiled, targeted therapeutic
strategies (e.g. the use of a selective PNDC to reduce PN levels) will
become more attractive for the long-term treatment of pain. It is also
of interest to note that PNDCs are able to synergize with other analge-
sics including non-selective COX-1/COX-2 inhibitors, selective COX-2
inhibitors [20], and opiates (Salvemini, unpublished observations).
This would allow for these drugs to be used at lower dosages, increasing
their efﬁcacy and reducing the risk of intolerable side effects. Thus
whether used alone or in combination with other analgesics, the
potential impact these agents could have both to individuals and society
would be indescribable.
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